Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group..

Blood. 2012 Jun 7;119(23):5374-83. doi: 10.1182/blood-2011-11-392522. Epub 2012 Apr 12.

2.

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.

Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.

Br J Haematol. 2014 Jul;166(1):109-17. doi: 10.1111/bjh.12861. Epub 2014 Mar 27.

PMID:
24673708
3.

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group..

Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3.

4.

Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.

Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA.

Clin Cancer Res. 2013 Nov 1;19(21):6030-8. doi: 10.1158/1078-0432.CCR-12-3211. Epub 2013 Aug 30.

5.

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE; National Cancer Research Institute Haematological Oncology Clinical Studies Group..

Lancet Oncol. 2011 Aug;12(8):743-52. doi: 10.1016/S1470-2045(11)70157-7. Epub 2011 Jul 21.

6.

Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.

Delea TE, Rotter J, Taylor M, Chandiwana D, Bains M, El Ouagari K, Kaura S, Morgan GJ.

J Med Econ. 2012;15(3):454-64. doi: 10.3111/13696998.2011.653511. Epub 2012 Feb 9.

PMID:
22316275
7.

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.

Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC.

Eur J Haematol. 2012 Jan;88(1):1-7. doi: 10.1111/j.1600-0609.2011.01721.x. Epub 2011 Nov 22. Review.

8.

Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?

Morgan GJ.

Crit Rev Oncol Hematol. 2011 Feb;77 Suppl 1:S24-30. doi: 10.1016/S1040-8428(11)70005-1. Review.

PMID:
21353177
9.

The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.

Berenson JR.

Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):2-4. doi: 10.1016/j.clml.2011.03.025. Epub 2011 May 4. No abstract available.

PMID:
22130220
10.

The impact of response on bone-directed therapy in patients with multiple myeloma.

Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A, Gregory WM, Brioli A, Owen RG, Drayson MT, Wu P, Palumbo A, Boccadoro M, Davies FE, Morgan GJ.

Blood. 2013 Oct 24;122(17):2974-7. doi: 10.1182/blood-2013-04-498139. Epub 2013 Aug 23.

11.

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, GarcĂ­a-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD.

J Clin Oncol. 2013 Jun 20;31(18):2347-57. doi: 10.1200/JCO.2012.47.7901. Epub 2013 May 20.

12.

Bisphosphonates in multiple myeloma: a network meta-analysis.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2012 May 16;(5):CD003188. doi: 10.1002/14651858.CD003188.pub3. Review.

PMID:
22592688
13.

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.

Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, D'Arco A, Ronconi S, Cellini C, Offidani M, Perrone G, Ceccolini M, Brioli A, Tura S, Baccarani M, Cavo M.

Blood. 2006 Dec 1;108(12):3951-2. No abstract available.

14.

Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.

Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):326-35. doi: 10.1016/j.clml.2011.04.004. Epub 2011 May 6.

PMID:
21700528
15.

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.

Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R, Hadala JT, Warsi G, Argonza-Aviles E, Ericson SG, Anderson KC.

Clin Cancer Res. 2016 Mar 15;22(6):1378-84. doi: 10.1158/1078-0432.CCR-15-1864. Epub 2015 Dec 7.

16.

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A; GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network..

Cancer. 2008 Oct 1;113(7):1588-95. doi: 10.1002/cncr.23783. Erratum in: Cancer. 2008 Nov 15;113(10):2835.

17.

Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.

Henk HJ, Teitelbaum A, Perez JR, Kaura S.

Am J Hematol. 2012 May;87(5):490-5. doi: 10.1002/ajh.23164. Epub 2012 Mar 27.

18.
19.

Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.

Van den Wyngaert T, Delforge M, Doyen C, Duck L, Wouters K, Delabaye I, Wouters C, Wildiers H.

Support Care Cancer. 2013 Dec;21(12):3483-90. doi: 10.1007/s00520-013-1934-0. Epub 2013 Aug 18.

PMID:
23955094
20.

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.

Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group..

Haematologica. 2012 Mar;97(3):442-50. doi: 10.3324/haematol.2011.043372. Epub 2011 Nov 4.

Supplemental Content

Support Center